$5.25 Million in Sales Expected for Kala Pharmaceuticals Inc (NASDAQ:KALA) This Quarter

Analysts expect Kala Pharmaceuticals Inc (NASDAQ:KALA) to announce $5.25 million in sales for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for Kala Pharmaceuticals’ earnings. The highest sales estimate is $6.50 million and the lowest is $4.27 million. The company is scheduled to report its next quarterly earnings report on Monday, March 9th.

According to Zacks, analysts expect that Kala Pharmaceuticals will report full-year sales of $12.35 million for the current fiscal year, with estimates ranging from $10.91 million to $14.40 million. For the next financial year, analysts anticipate that the firm will report sales of $59.56 million, with estimates ranging from $35.08 million to $94.71 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that cover Kala Pharmaceuticals.

Kala Pharmaceuticals (NASDAQ:KALA) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.01). The firm had revenue of $1.45 million during the quarter, compared to analyst estimates of $3.56 million.

Several equities analysts recently commented on the company. JPMorgan Chase & Co. dropped their target price on Kala Pharmaceuticals from $22.00 to $14.00 and set an “overweight” rating on the stock in a report on Friday. ValuEngine raised Kala Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Zacks Investment Research raised Kala Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.25 target price on the stock in a report on Wednesday. Wedbush reissued an “outperform” rating and issued a $51.00 target price on shares of Kala Pharmaceuticals in a report on Wednesday, August 7th. Finally, HC Wainwright dropped their target price on Kala Pharmaceuticals from $15.00 to $12.00 and set a “buy” rating on the stock in a report on Wednesday, August 7th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Kala Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $17.54.

Kala Pharmaceuticals stock traded up $0.40 during mid-day trading on Thursday, hitting $4.11. The company’s stock had a trading volume of 374,000 shares, compared to its average volume of 249,192. The firm has a market capitalization of $126.17 million, a PE ratio of -1.66 and a beta of 2.13. The stock’s fifty day moving average is $3.84 and its two-hundred day moving average is $5.11. The company has a current ratio of 7.50, a quick ratio of 7.04 and a debt-to-equity ratio of 1.16. Kala Pharmaceuticals has a 1 year low of $3.24 and a 1 year high of $9.25.

Several hedge funds have recently modified their holdings of the business. BlackRock Inc. grew its holdings in shares of Kala Pharmaceuticals by 20.3% during the second quarter. BlackRock Inc. now owns 1,684,802 shares of the company’s stock worth $10,749,000 after purchasing an additional 283,747 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Kala Pharmaceuticals by 25.1% during the second quarter. Vanguard Group Inc. now owns 1,237,683 shares of the company’s stock worth $7,896,000 after purchasing an additional 248,287 shares during the last quarter. Northern Trust Corp grew its holdings in shares of Kala Pharmaceuticals by 4.9% during the second quarter. Northern Trust Corp now owns 198,260 shares of the company’s stock worth $1,265,000 after purchasing an additional 9,183 shares during the last quarter. Boston Partners grew its holdings in shares of Kala Pharmaceuticals by 542.6% during the second quarter. Boston Partners now owns 118,431 shares of the company’s stock worth $756,000 after purchasing an additional 100,000 shares during the last quarter. Finally, Wedbush Securities Inc. grew its holdings in shares of Kala Pharmaceuticals by 163.9% during the third quarter. Wedbush Securities Inc. now owns 89,225 shares of the company’s stock worth $340,000 after purchasing an additional 55,410 shares during the last quarter. 68.84% of the stock is currently owned by institutional investors.

Kala Pharmaceuticals Company Profile

Kala Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's lead product candidate is KPI-121 0.25% which has completed two Phase III clinical trials for the treatment of temporary relief of the signs and symptoms of dry eye disease; INVELTYS which has completed two Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases.

Further Reading: What is systematic risk?

Get a free copy of the Zacks research report on Kala Pharmaceuticals (KALA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Kala Pharmaceuticals (NASDAQ:KALA)

Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.